statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LONDON, April 03, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) ( Mereo or the Company ), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...

Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

For the last three days, A.I.dvisor has detected that MREO's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

Mereo BioPharma Group (MREO, $3.41) Aroon Indicator entered a Downtrend on April 01, 2024.

Mereo BioPharma Group (NASDAQ:MREO - Free Report) had its price target lifted by Needham & Company LLC from $5.00 to $6.00 in a report published on Thursday, Benzinga reports. Needham & Company LLC...

Needham & Company LLC Boosts Mereo BioPharma Group (NASDAQ:MREO) Price Target to $6.00

This indicator may be signaling MREO's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...

Mereo BioPharma Group plc (MREO, $3.3) entered Uptrend as Momentum indicator ascends above 0 level on Mar 28, 2024

Mereo BioPharma Group (NASDAQ:MREO  Get Free Report) had its target price hoisted by equities research analysts at Needham  Company LLC from $5.00 to $6.00 in a research report issued on...

Mereo BioPharma Group (NASDAQ:MREO) Price Target Raised to $6.00

This is a signal that MREO's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

Mereo BioPharma Group (MREO, $3.02) RSI Indicator left the oversold zone on March 27, 2024

Setrusumab and Alvelestat Progress as Company Prepares for Transformative 2024Related Stocks: MREO...

Mereo BioPharma Group PLC (MREO) Announces Full Year 2023 Financial Results

Phase 2/3 Orbit Study and Phase 3 Cosmic Study of setrusumab in Osteogenesis Imperfecta expected to complete enrollment around the end of first quarter and in the first half of 2024, respectively...

Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update

Mereo BioPharma Group (NASDAQ:MREO  Get Free Report)s stock had its overweight rating reissued by analysts at Cantor Fitzgerald in a research note issued to investors on...

Cantor Fitzgerald Reiterates Overweight Rating for Mereo BioPharma Group (NASDAQ:MREO)

Mereo BioPharma Group (MREO, $3.04) Aroon Indicator entered a Downtrend on March 19, 2024.

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.

Volume	1.03M
52-Wk High	$4.36
52-Wk Low	$0.9201

MREO Mereo Biopharma

About

Feed

News

Sentiment

Fundamentals